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DObjective: Transcatheter aortic valve implantation (TAVI) has emerged as an alternative treatment to aortic
valve replacement (AVR) for selected patients with severe aortic stenosis. The present systematic review was
conducted to analyze the cost-effectiveness of this novel technique within reimbursed healthcare systems.
Methods: Two reviewers used 7 electronic databases from January 2000 to November 2012 to identify relevant
cost-effectiveness studies of TAVI versus AVR or medical therapy. The primary endpoints were the incremental
cost-effectiveness ratio (ICER) and the probability of cost-effectiveness. The eligible studies for the present
systematic review included those in which the cost-effectiveness data were measured or projected for TAVI
and either medical therapy or AVR. All forms of TAVI were included, and all retrieved publications were limited
to the English language.
Results: Eight studies were included for quantitative assessment. The ICER for TAVI compared with medical
therapy for surgically inoperable patients ranged from US$26,302 to US$61,889 per quality-adjusted life year
gained. The probability of TAVI being cost-effective compared with medical therapy ranged from 0.03 to 1.00.
The ICER values for TAVI compared with AVR for high-risk surgical candidates ranged from US$32,000 to
US$975,697 per quality-adjusted life year gained. The probability of TAVI being cost-effective in this cohort
ranged from 0.116 to 0.709.
Conclusions: Depending on the ICER threshold selected, TAVI is potentially justified on both medical and
economic grounds compared with medical therapy for patients deemed to be surgically inoperable. However,
in the high-risk surgical patient cohort, the evidence is currently insufficient to economically justify the use
of TAVI in preference to AVR. (J Thorac Cardiovasc Surg 2014;148:509-14)Aortic stenosis (AS) is the most common form of valvular
heart disease in developed nations, with a reported
12-month mortality rate of>30% for medically treated
symptomatic patients.1 Surgical aortic valve replacement
(AVR) has long been the accepted standard of care for
patients with symptomatic AS. However, the emergence
of transcatheter aortic valve implantation (TAVI), using
either a percutaneous or transapical approach, has provided
an alternative therapeutic option for selected patients.2
Although TAVI has demonstrated superior survival and
symptomatic outcomes for inoperable patients compared
with medical therapy in the Placement of Aortic
Transcatheter Valve (PARTNER) B trial, the evidence
assessing its role in high-risk operable surgical candidates
remains controversial.2,3he Systematic Review Unit,a Collaborative Research (CORE) Group,
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The Journal of Thoracic and CaEstablishing the cost-effectiveness of a new therapy
using standardizedmetrics is essential before its widespread
use in reimbursed healthcare systems. The evaluation of
the cost-effectiveness of a procedure relies on the
estimation of inputs, including the costs and clinical
outcomes experienced by patients. This can be achieved
using a trial-based or model-based approach. Typically,
cost-effectiveness measurements such as the incremental
cost-effectiveness ratio (ICER) will be calculated and
compared with national thresholds of economic efficiency,
with sensitivity analyses performed to examine the
probability of the procedure remaining or becoming cost-
effective after input parameter modification.
Despite an exponential growth in the performance of
TAVI in many European and North American centers, a
paucity of robust clinical data remains to assess the
cost-effectiveness of this relatively novel technique. The
present systematic review aimed to assess TAVI compared
with AVR and medical therapy for patients with severe
AS using ICER and the probability of cost-effectiveness
as the primary endpoints.
METHODS
Data Search Strategy
Electronic data searches were performed using Ovid Medline, PubMed,
EMBASE, National Health Service Economic Evaluation Database,rdiovascular Surgery c Volume 148, Number 2 509
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
ICER ¼ incremental cost-effectiveness ratio
PARTNER ¼ Placement of Aortic Transcatheter
Valve
QALY ¼ quality-adjusted life year
TAVI ¼ transcatheter aortic valve implantation
WTPT ¼ willingness-to-pay threshold
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DAmerican College of Physicians Journal Club, Database of Abstracts of
Review of Effects, and Cochrane Database of Systematic Reviews from
January 2000 to November 2012. To maximize the sensitivity of the search,
we combined the terms ‘‘transcatheter’’ or ‘‘transapical’’ or ‘‘transfe-
moral’’ or ‘‘transcutaneous’’ or ‘‘transvascular’’ or ‘‘percutaneous’’ with
‘‘aortic valve’’ or ‘‘aortic valve stenosis’’ or ‘‘TAVI’’ or ‘‘transcatheter
aortic valve implantation’’ or ‘‘transcatheter aortic valve replacement’’
and ‘‘economics’’ or ‘‘cost’’ or ‘‘cost-utility’’ or ‘‘cost-effectiveness’’ or
‘‘cost-benefit analysis’’ as either key words or MeSH terms. After an initial
screening of the titles and abstracts, the full text of the potentially relevant
studies was obtained for additional evaluation. The reference lists of all
retrieved studies were reviewed for identification of additional relevant
studies.
Selection Criteria
The eligible studies for the present systematic review included those in
which the cost-effectiveness data were measured or projected for TAVI and
either medical therapy or AVR. All forms of TAVI were included,
regardless of the anatomic approach or type of valve used. All publications
retrieved were limited to those in the English language. Abstracts, case
reports, editorials, letters, conference presentations, and expert opinions
were excluded.
Data Extraction and Critical Appraisal
All data were extracted from the article text, tables, and figures.
Two investigators (P.I. and S.A.) independently reviewed each retrieved
report. Discrepancies between the 2 reviewers were resolved by discussion
and consensus. The final results were reviewed by the senior investigators
(C.C. and T.D.Y.).RESULTS
Quantity and Quality of Studies
Using the predefined search strategy, 161 references were
retrieved for the initial screening, as summarized in the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis chart in Figure 1. After applying the
predetermined selection criteria, 8 studies remained for
analysis and inclusion in the present review.4-11 Of these,
4 studies had included data collected from the PARTNER
trials4,5,7,10 and 4 had included registry data or published
data review.6,8,9,11 Six studies described model-based
evaluations performed in the context of different interna-
tional healthcare systems.4-8,11 Of these, 2 had compared
the cost-effectiveness of TAVI against medical management
for patients with severe AS deemed to be inoperable,5,6 and
the remaining 4 studies compared TAVI with medical510 The Journal of Thoracic and Cardiovascular Surgtreatment and AVR.4,7,8,11 Two studies had used
retrospective clinical trial data without economic
modeling.9,10 Osnabrugge and colleagues9 reported a
propensity-matched retrospective analysis comparing the
costs of TAVI and AVR among ‘‘intermediate surgical
risk’’ patients. Reynolds and colleagues10 reported a
prospective analysis of the PARTNER A study comparing
the costs of TAVI and AVR during a 12-month period.
Themodel-based evaluations used differentmethods to es-
timate the future costs and outcomes of the procedures (Table
1). A Markov model or a similar statistical technique was
used for the cost projections, and the probabilities of transi-
tioning between cycles in the model were derived from the
PARTNER study,5 registry data,8,11 or published data
review.4,6,7 The total expense of TAVI, AVR, and medical
management calculated using each model included the
costs of the procedure, initial hospitalization, perioperative
and long-term complications, repeat hospitalizations, physi-
cian fees, and drug costs. These costswere derived using gov-
ernment data, hospital billing data, or data collected from the
PARTNER studies.2,12 The time horizons of all studies varied
from 12 months to lifetime. The selection of this period was
determined from the outcomes of the PARTNER A trial,
which did not demonstrate any significant changes in
mortality after 1 year. In addition, only 1 study presented
data on the costs of preoperative investigations specific to
TAVI,9 and the cost-effectiveness of performing concomitant
cardiac surgery with AVR was not assessed. The quality of
life was estimated using published utility weights,8,11 the
results of the EuroQOL 5 dimensions (EQ-5D)
questionnaire,4,5,10 or a New York Heart Association class
transformation approach.4,6,7 The rate of annual
discounting ranged from 1.5% to 5.0%. All studies
included a sensitivity analysis in which various
hypothetical parameters were removed, applied, or
modified to assess the stability of the results. Examples
included the cost of the TAVI valve,4-6 hospitalization
costs,6,9,10 and the rate of perioperative6,8 and long-term com-
plications.7,8,11 Probabilistic sensitivity analyses were
included in 6 of the 8 studies in the present systematic
review.4-7,10,11
Cost-Effectiveness of TAVI Versus Medical Therapy
ICER has been the most commonly used economic
parameter in determining the economic efficiency of a
novel therapeutic procedure, and it was reported in all
comparative studies identified in the present systematic
review.4-11 The ICER of 1 treatment compared with
another has been defined as the cost required to gain 1
additional quality-adjusted life year (QALY).13 If a
treatment produces an improvement in the QALYs gained
at less expense, it would be considered economically
dominant. The ICER thresholds of acceptability vary
among countries and are not rigid.ery c August 2014
FIGURE 1. Preferred reporting items for systematic reviews and meta-analysis flow diagram summarizing the search strategy.
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DThe projected costs of TAVI were consistently greater
than medical therapy; however, TAVI was shown to
improve the quality of life by 0.60 to 1.56 QALYs.4-7 The
ICER values ranged from US $26,302 to $61,889 per
QALY gained (PQG; Table 2). Neyt and colleagues4 foundTABLE 1. Summary of study characteristics comparing costs after TAVI
Investigator Year Country Model type
Com
again
Neyt et al4 2012 Belgium Single Markov model MT a
Reynolds et al5 2012 US Parametric survival model MT o
Watt et al6 2012 UK Double Markov models MT o
Doble et al7 2012 Canada Decision tree for short
term and Markov model
for long term
MT a
Gada et al8 2012 US Single Markov model MT a
(TF
Osnabrugge et al9 2012 The
Netherlands
No projection model used AVR
Reynolds et al10 2012 US No projection model used AVR
Gada et al11 2012 US Single Markov model MT a
(TA
TAVI, Transcatheter aortic valve implantation; AVR, aortic valve replacement;MT, medical
TF, transfemoral; TA, transapical.
The Journal of Thoracic and Cathe ICER to be approximatelyV10,000 (US$13,043) less in
a subgroup of ‘‘anatomically’’ inoperable patients
compared with ‘‘medically’’ inoperable patients. The prob-
abilistic sensitivity analyses demonstrated a wide variation
in the results, as determined by the willingness-to-payand AVR or medical therapy
parison
st TAVI
TAVI population
group
Simulations
or patients (n) Time horizon
nd AVR PARTNER A and
B cohorts
1000 12 mo for high-risk;
lifetime for
inoperable
nly PARTNER B cohort 358 Lifetime
nly PARTNER B cohort 1000 Lifetime
nd AVR PARTNER A and
B cohorts
NR 20 y
nd AVR
-TAVI)
Registry data and
PARTNER A cohort
10,000 Lifetime
only Intermediate surgical
risk patients
84 matched
patients
12 mo
only PARTNER A cohort 340 TAVI
307 AVR
12 mo
nd AVR
-TAVI)
Registry data 10,000 Lifetime
therapy; PARTNER, Placement of Aortic Transcatheter Valve trial; NR, not reported;
rdiovascular Surgery c Volume 148, Number 2 511
TABLE 2. Projected raw costs and incremental cost-effectiveness ratio for transcatheter aortic valve implantation versus medical therapy
Investigator
QALYs
gained by TAVI
Projected mean raw cost Discounting
rate (%)
ICER (local
currency PQG)
ICER
($US PQG)*
WTPT used
($US PQG)*
Probability of
cost-effectivenessTAVI MT
Neyt et al4 1.30 EUR 43,571 EUR 3,170 3.0 EUR 44,900 58,567 47,141 0.37
31,427 0.09
Reynolds et al5 1.30 USD 149,740 USD 69,903 3.0 USD 61,889 61,889 50,000 0.03
100,000 1.00
Watt et al6 1.56 GBP 30,200 GBP 5,000 3.5 GBP 16,200 26,302 31,439 1.00
Doble et al7 0.60 CAD 88,991 CAD 57,963 5.0 CAD 51,324 52,628 48,672 0.441
Gada et al8 NR USD 59,503 NR 5.0 USD 39,964 39,964 100,000 NR
Gada et al11 NR USD 56,730 NR 5.0 USD 44,384 44,384 100,000 NR
QALY, Quality-adjusted life-year; TAVI, transcatheter aortic valve implantation; MT, medical therapy; ICER, incremental cost-effectiveness ratio; WTPT, willingness-to-pay
threshold; PQG, per quality-adjusted life year gained; EUR, Euros; USD, US dollars; GBP, British pounds; CAD, Canadian dollars. *Converted to US dollars using exchange
rates from www.xe.com, September 19, 2012.
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cost-effective compared with medical therapy ranged
from 0.03 to 1.00. Reynolds and colleagues10 found the
probability of TAVI being cost-effective at a WTPT of US
$50,000 of 0.03. However, at a WTPT of US $100,000,
this probability increased to 1.00.5
Cost-Effectiveness of TAVI Versus AVR
TAVI was reported to be more costly than AVR in all
studies,4,7-11 apart from the transfemoral TAVI subgroup
analyzed by Reynolds and colleagues.10 The number of
QALYs gained by TAVI compared with AVR in high-risk
surgical candidates ranged from 0.102 to 0.068.4,7-11
Three studies reported TAVI to be economically
dominated by AVR.7,10,11 Of these 3 analyses, 2 were
limited to transapical TAVI.10,11 In contrast, Reynolds and
colleagues10 found that TAVI using the transfemoralTABLE 3. Projected raw costs of incremental cost-effectiveness ratio of
replacement
Investigator
QALYs gained
by TAVI
Projected mean raw cost Discountin
rate (%)TAVI AVR
Neyt et al4 0.03 EUR 43,571 EUR 23,749 3.0
Doble et al7 0.102 CAD 85,755 CAD 74,602 5.0
Gada et al8 0.06
(reference case)
USD 59,503 USD 56,339 5.0
Gada et al8 0.01 (PARTNER
scenario)
USD 85,513 USD 82,989 5.0
Gada et al8 0.06 (combined) USD 81,446 USD 79,526 5.0
Osnabrugge et al9 0.068y EUR 46,217 EUR 35,511 NA
Reynolds et al10 0.027 (TF- and
TA-TAVI)
USD 100,504 USD 98,434 NA
Reynolds et al10 0.068 (TF-TAVI) USD 96,743 USD 97,992 NA
Reynolds et al10 0.070 (TA-TAVI) USD 109,405 USD 99,499 NA
Gada et al11 0.04 (TA-TAVI) USD 56,730 USD 56,630 5.0
QALY, Quality-adjusted life-year; TAVI, transcatheter aortic valve implantation; AVR, aorti
reported;CAD, Canadian dollars;NA, not applicable;USD, US dollars; PARTNER, Placeme
USD using exchange rates from www.xe.com, September 19, 2012. yThe study did not ev
512 The Journal of Thoracic and Cardiovascular Surgapproach was economically dominant compared with
AVR.10 In the other analyses that did not establish economic
dominance for either treatment modality, marked
heterogeneity was present for the reported ICER values
for TAVI versus AVR, ranging from US $32,000 to
$975,697 (Table 3).4,9,11
The retrospective 12-month observational study
performed by Osnabrugge and colleagues9 demonstrated
an incremental cost of V10,706 (US $13,669), favoring
AVR.9 Because no quality of life data were collected, a
figure of 0.068 QALYs gained, as quoted by the PARTNER
study, was used to calculate the ICER for that study. In their
analysis of transfemoral TAVI, Gada and colleagues8
performed multiple analyses using 3 separate sets of
data. These included an index case based on registry
data, an analysis based on the PARTNER A study, and a
third analysis that combined the costs reported in thetranscatheter aortic valve implantation versus surgical aortic valve
g ICER (local
currency PQG)
ICER
($US PQG)*
WTPT
($US PQG)*
Probability of
cost-effectiveness
EUR 750,000 975,697 47,141 NR
Dominated by AVR NA 48,672 0.116
USD 52,773 52,773 100,000 NR
USD 252,400 252,400 100,000 NR
USD 32,000 32,000 100,000 NR
EUR 157,441 204,819 NR NR
USD 76,877
(TF- and TA-TAVI)
76,877 50,000 0.438
AVR dominated by
TF-TAVI
NA 50,000 0.709
TA-TAVI dominated
by AVR
NA 50,000 0.071
Dominated by AVR NA 100,000 0.47
c valve replacement; ICER, incremental cost-effectiveness ratio; EUR, euros; NR, not
nt of Aortic Transcatheter Valve trial; TF, transfemoral; TA, transapical. *Converted to
aluate quality of life, and a value of 0.06 was used to calculate the ICER.
ery c August 2014
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The ICER of the PARTNER scenario analysis far exceeded
that of the index case and combined analysis (Table 3).
Sensitivity analyses were performed in all studies to
identify the potential parameters that might significantly
influence the cost-effectiveness of TAVI. Gada and
colleagues11 noted that a reduction in the 12-month
mortality rate of transapical TAVI from 25.28% to 24%
would significantly alter the analysis, rendering TAVI
economically dominant. The probabilistic sensitivity
analyses demonstrated that the probability of TAVI
being cost-effective compared with AVR ranged from
0.071 to 0.709.
DISCUSSION
The present study represents the first systematic review to
assess the cost-effectiveness of TAVI compared with other
treatment modalities for patients with symptomatic AS.
Separate comparisons were made for TAVI versus medical
therapy in inoperable patients and TAVI versus surgical
AVR in high-risk operable patients using the ICER and
the probability of cost-effectiveness. Nation-specific
ICER thresholds of acceptability have varied widely,
depending on the financial structure and revenue patterns
of the healthcare system in question.14 It has been suggested
that for an intervention to be considered cost-effective, its
ICER value should not exceed 3 times that of the nation’s
per capita gross domestic product, although these
thresholds have generally been used as guidelines.15 In
the US healthcare system, no definite ICER threshold for
acceptability has been established. However, costs less
than US $50,000 PQG have generally been accepted as
cost-effective, and costs of US $50,000 to $100,000 PQG
have been considered to be within an intermediate zone of
uncertainty.16 Such thresholds have been used for guidance
only and have rarely been the sole discriminator of
cost-effectiveness within an economic system.
The findings of the present study have demonstrated that
the projected ICER of TAVI compared with medical therapy
for inoperable patients ranged from $26,302 PQG to
$61,889 PQG.4-7 The probability of cost-effectiveness
largely depended on the WTPT used in the individual
studies. This was demonstrated by Reynolds and col-
leagues,5 who reported a probability of 0.03 to 1.00 for
the cost-effectiveness of TAVI compared with medical ther-
apy, depending on the proposedWTPT. However, even after
modification of the model parameters within the sensitivity
analyses, TAVI remained economically attractive compared
with the medical treatment at the US $100,000 PQG
threshold. The cost-effectiveness of TAVI compared with
medical therapy would likely be greater for patients deemed
inoperable for anatomic reasons, such as a porcelain aorta,
chest wall deformity, or previous thoracic radiotherapy.
These patients will be more likely to experience favorableThe Journal of Thoracic and Caoutcomes after TAVI procedures because of having fewer
medical comorbidities.4 Overall, despite the much greater
initial costs, the improvement in the quality and longevity
of life suggests that TAVI might be an efficacious
and cost-effective alternative to medical therapy for
symptomatic inoperable patients.
However, the data from the present review did not
conclusively demonstrate that TAVI is incrementally
cost-effective compared with AVR for high-risk surgical
candidates, because of the wide variability of ICER values
and probabilities of economic acceptability reported. Of
the 9 analyses, 6 reported an ICER value that would have
been deemed unacceptable using a US $100,000 PQG
threshold4,7,8,10,11 and 7 would have been deemed
unacceptable using a US $50,000 PQG threshold.4,7-11
Only 1 sensitivity analysis demonstrated a probability of
economic acceptability >0.5.10 Four analyses suggested
TAVI to be a cost-effective alternative to AVR using a
WTPT of US $100,000 PQG. These were the analyses
involving transfemoral TAVI using registry data published
by Gada and colleagues8 and Reynolds and colleagues,10
both of which were based in the United States. The cost
differences between the transfemoral and transapical
approaches to TAVI were only analyzed in 1 study, which
suggested significant differences in expense favoring the
transfemoral approach, possibly owing to differences in
comorbidities.10,17
A number of factors could have contributed to the wide
variations in the results among the individual analyses.
These included differing materials costs, hospitalization
costs, complication rates, and the nature and duration of
the mathematical projection model used. For example, in
the United States, the total costs of TAVI and AVR were
generally similar, because the more costly device- and
procedure-related expenses for TAVI were offset by the
comparatively greater costs of hospitalization after AVR.
The costs of hospitalization in the United States are
6 times greater than those in European countries.18
Another significant difference between the treatment
approaches is the cost of the valvular device. The
Edwards-SAPIEN valve (Edwards Lifesciences, Irvine,
Calif) has a reported cost of US $23,000 to $30,000.5,10
This was significantly greater than the cost of the typical
bioprosthetic valve used in AVR at approximately US
$3500.9 Of the studies that compared TAVI with AVR,
only 1 examined a reduction in the TAVI valve cost in the
sensitivity analysis. In that analysis, the ICER remained
unacceptably high.4 Adding to the observed variability
was the heterogeneous sources of data used for the clinical
outcomes, costs, and quality of life. Three studies used
registry data in their analysis,8,9,11 and the remainder used
data from the PARTNER trials4,5,7,10 or published data
review.6 Gada and colleagues8 found the ICER value
calculated using data from the PARTNER trial far exceededrdiovascular Surgery c Volume 148, Number 2 513
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outcomes and costs in the standard clinical setting might
differ from that of a randomized control trial. This
might have partly resulted from the different baseline
characteristics of the patients included in registries and
randomized trials.
It should be acknowledged that all the model-based
evaluations included in the present systematic review
were based on the PARTNER trials and limited to the
Edwards-SAPIEN valve (Edwards Lifesciences), with
only 1 exception.9 Other randomized controlled trials
comparing TAVI and AVR also exist in the published
data, including the STACCATO trial, which was
prematurely terminated owing to excessive morbidity and
mortality in the TAVI group.19 The long-term efficacy of
TAVI bioprostheses remains largely unknown, and potential
complications such as valvular insufficiency beyond the
existing follow-up periods could result in additional
hospitalizations and increased costs greater than the present
estimates. A cost analysis of the CoreValve (Medtronic,
Minneapolis, Minn) might be possible in the near future
after the completion of randomized controlled trials
currently underway.20 The existence of a single completed
randomized controlled trial in the published data has
limited the available comparative morbidity and mortality
outcomes used in cost projection analyses.
CONCLUSIONS
The present systematic review showed that TAVI is
potentially a cost-effective alternative to medical therapy
for inoperable patients with symptomatic AS in selected
healthcare settings. Although the raw costs of TAVI are
greater, the procedure has been associated with a significant
gain in quality-adjusted life years compared with medical
management. However, in high-risk but operable surgical
candidates, current data suggest that TAVI might not be a
viable economic alternative to AVR. This could possibly
change in the near future, as TAVI operators obtain more
procedural experience and reduce perioperative morbidity
and mortality to improve the cost-effectiveness for TAVI.
In addition, it has been anticipated that advances in
technology and material cost discounts will further decrease
the ICER of TAVI. Nation-specific cost-effectiveness
evaluations are recommended, because the threshold for
economic acceptability depends on a nation’s societal
utility values and revenue patterns.
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